Delving into the Latest Updates on Parke-Davis Pharmaceutical Research, Inc. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

DRDs(多巴胺受体家族)	1

关联

1

项与 Parke-Davis Pharmaceutical Research, Inc. 相关的药物

CI-1007

靶点

DRDs

作用机制

DRDs激动剂

在研机构

Parke-Davis Pharmaceutical Research, Inc.

原研机构

Pfizer Inc.

在研适应症

精神障碍

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Parke-Davis Pharmaceutical Research, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Parke-Davis Pharmaceutical Research, Inc. 相关的专利（医药）

登录后查看更多信息

428

项与 Parke-Davis Pharmaceutical Research, Inc. 相关的文献（医药）

2020-08-18·Biological Inhibitors

Dual Inhibitors of 5-Lipoxygenase and Cyclooxygenase

作者: Connor, David T. ; Boschelli, Diane H.

A review, with 185 references, on inhibitors of 5-lipoxygenase and cyclooxygenase which should down-regulate an inflammatory response.It appears that a dual inhibitor can be a superior anti-inflammatory drug.

2013-03-01·Int. Journal of Clinical Pharmacology and Therapeutics4区 · 医学

Bioequivalence assessment of a pregabalin capsule and oral solution in fasted healthy volunteers: a randomized, crossover study

4区 · 医学

Article

作者: Bockbrader, Howard N. ; Alvey, Christine W. ; Radulovic, Louis L. ; Corrigan, Brian W.

OBJECTIVETo determine the oral bioavailability of a pregabalin capsule relative to a pregabalin solution.METHODSThis was an open-label, randomized, crossover study in 12 healthy volunteers. Pharmacokinetics were compared for a 100-mg capsule and a 100-mg capsule dissolved in water, administered fasted.RESULTSMean Cmax and AUC0-∞ for the capsule were within 2% of those for the solution (3.8 vs. 3.7 μg/ml and 26.7 vs. 27.0 μg×h/ml, respectively). The 90% confidence intervals for the ratios of Cmax and AUC0-∞ fell fully within 80 - 125%.CONCLUSIONSA 100-mg pregabalin capsule is bioequivalent to a pregabalin solution (100-mg capsule dissolved in water).

2002-10-01·Journal of Computational Biology4区 · 生物学

Mining Protein Sequences for Motifs

4区 · 生物学

Article

作者: Narasimhan, Giri ; Gao, Yuan ; Mathee, Kalai ; Wang, Xuning ; Bu, Changsong ; Xu, Ning

We use methods from Data Mining and Knowledge Discovery to design an algorithm for detecting motifs in protein sequences. The algorithm assumes that a motif is constituted by the presence of a "good" combination of residues in appropriate locations of the motif. The algorithm attempts to compile such good combinations into a "pattern dictionary" by processing an aligned training set of protein sequences. The dictionary is subsequently used to detect motifs in new protein sequences. Statistical significance of the detection results are ensured by statistically determining the various parameters of the algorithm. Based on this approach, we have implemented a program called GYM. The Helix-Turn-Helix motif was used as a model system on which to test our program. The program was also extended to detect Homeodomain motifs. The detection results for the two motifs compare favorably with existing programs. In addition, the GYM program provides a lot of useful information about a given protein sequence.

100 项与 Parke-Davis Pharmaceutical Research, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Parke-Davis Pharmaceutical Research, Inc. 相关的转化医学

登录后查看更多信息